Search hospitals > Alberta > EDMONTON

Stollery Children's Hospital

Claim this profile
EDMONTON, Alberta T6G 2B7
Conducts research for Congenital Heart Diseases
Conducts research for Vestibular Migraine
Conducts research for Migraine
Conducts research for Brain Tumor
Conducts research for Adult T-Cell Leukemia/Lymphoma
96 reported clinical trials
12 medical researchers
Photo of Stollery Children's Hospital in EDMONTONPhoto of Stollery Children's Hospital in EDMONTONPhoto of Stollery Children's Hospital in EDMONTON

Summary

Stollery Children's Hospital is a medical facility located in EDMONTON, Alberta. This center is recognized for care of Congenital Heart Diseases, Vestibular Migraine, Migraine, Brain Tumor, Adult T-Cell Leukemia/Lymphoma and other specialties. Stollery Children's Hospital is involved with conducting 96 clinical trials across 237 conditions. There are 12 research doctors associated with this hospital, such as Sarah J. McKillop, Hien Huynh, Andrew Dixon, MD, and Sunil Desai, M.B.Ch.B., FRCP(c).

Top PIs

Clinical Trials running at Stollery Children's Hospital

Brain Tumor
Hemophilia B
Vestibular Migraine
Migraine
Obesity
Solid Tumors
Haemophilia A, Haemophilia B, Obesity
Hemophilia A
Vasculitis
Lymphoma
Image of trial facility.

Metformin

for Medulloblastoma Recovery

The efficacy of treatment with metformin for promoting cognitive recovery and brain growth in children/adolescents treated for a brain tumour will be investigated in a multi-site Phase III randomized double-blind placebo-controlled parallel arm superiority trial. Specifically, in children/adolescents aged 7 years to 21 years and 11 months who have completed treatment for a brain tumour, is oral administration of metformin for 16 weeks associated with greater improvement of cognitive function and brain growth compared to placebo administered for 16 weeks?
Recruiting3 awards Phase 312 criteria
Image of trial facility.

DAY101 vs. Chemotherapy

for Pediatric Brain Cancer

This trial is testing tovorafenib, a medication given alone, in children with a specific type of brain tumor. The drug works by blocking a protein that helps cancer cells grow.
Recruiting2 awards Phase 3
Image of trial facility.

Repotrectinib

for Solid Tumors in Young Patients

Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations to estimate the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) and select the Pediatric Recommended Phase 2 Dose (RP2D). Phase 2 will determine the anti-tumor activity of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring ROS1 or NTRK1-3 alterations.
Recruiting1 award Phase 1 & 214 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Stollery Children's Hospital?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security